Plasma Fractionation Market

1
Plasma Fractionation Market

• Plasma Fractionation Market Size is Expected to
  Reach 23.00 Billion by 2027 Says AMR

2
Prime Determinants of Growth  ?

• Increase in geriatric population across the
  world, surge in the incidence of rare diseases,
  rise in use of immunoglobulins in medicine, and
  emergence of plasma collection centers in
  different countries fuel the growth of the global
  plasma fractionation market. On the other hand,
  high cost of plasma derived products impedes the
  growth to some extent. Nevertheless, high growth
  potential in emerging economies is expected to
  pave the way for lucrative opportunities for the
  frontrunners in the industry.
• Read More 
• https//www.alliedmarketresearch.com/plasma-fracti
  onation-market

3
(No Transcript)
4
Covid-19 scenario

• The outbreak of covid-19 led to postponements of
  planned surgeries across the world. Cases of
  hospital admission were also declined
  substantially. This factor affected the global
  plasma fractionation market.
• Simultaneously, the pandemic has also given way
  to a steep decline in the count of blood
  donations and plasma collections.

5
Key market players 

• Bio product laboratory
• Biotest AG
• Takeda Pharmaceutical Company Limited
• CSL Ltd.
• Grifols SA
• Kedrion S.P.A (Kedrion Biopharma Inc.)
• LFB S. A.
• Octapharma AG
• Baxter International

6
Contact

• David Correa5933 NE Win Sivers
  Drive205, Portland, OR 97220United StatesToll
  Free 1-800-792-5285 UK 44-845-528-1300Hong
  Kong 852-301-84916India (Pune)
  91-20-66346060Fax [phone]help_at_alliedma
  rketresearch.comWeb https//www.alliedmarketrese
  arch.com  Follow Us on LinkedIn Twitter